WallStreetZenWallStreetZen

NASDAQ: INDP
Indaptus Therapeutics Inc Stock

$2.13-0.01 (-0.47%)
Updated Jul 19, 2024
INDP Price
$2.13
Fair Value Price
$1.57
Market Cap
$18.19M
52 Week Low
$1.56
52 Week High
$4.08
P/E
-1.2x
P/B
1.94x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$14.98M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
-$12M
Beta
1.15
Next Earnings
Aug 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A

INDP Overview

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INDP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

INDP ($2.13) is overvalued by 35.7% relative to our estimate of its Fair Value price of $1.57 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
INDP ($2.13) is not significantly undervalued (35.7%) relative to our estimate of its Fair Value price of $1.57 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
INDP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INDP due diligence checks available for Premium users.

Be the first to know about important INDP news, forecast changes, insider trades & much more!

INDP News

Valuation

INDP fair value

Fair Value of INDP stock based on Discounted Cash Flow (DCF)
Price
$2.13
Fair Value
$1.57
Overvalued by
35.70%
INDP ($2.13) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INDP ($2.13) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INDP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

INDP price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.2x
Industry
-18.27x
Market
29.62x

INDP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.94x
Industry
6.22x
INDP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

INDP's financial health

Profit margin

Revenue
$0.0
Net Income
-$3.8M
Profit Margin
0%
INDP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$10.9M
Liabilities
$1.6M
Debt to equity
0.17
INDP's short-term assets ($10.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INDP's short-term assets ($10.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INDP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INDP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.9M
Investing
$0.0
Financing
$316.0k
INDP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

INDP vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
INDP$18.19M-0.47%-1.20x1.94x
SYBX$18.15M-3.13%-0.19x1.36x
GLYC$18.31M-4.05%-0.49x0.63x
CANF$18.36M+15.38%-1.50x2.94x
IBIO$18.54M+1.90%-0.44x0.75x

Indaptus Therapeutics Stock FAQ

What is Indaptus Therapeutics's quote symbol?

(NASDAQ: INDP) Indaptus Therapeutics trades on the NASDAQ under the ticker symbol INDP. Indaptus Therapeutics stock quotes can also be displayed as NASDAQ: INDP.

If you're new to stock investing, here's how to buy Indaptus Therapeutics stock.

What is the 52 week high and low for Indaptus Therapeutics (NASDAQ: INDP)?

(NASDAQ: INDP) Indaptus Therapeutics's 52-week high was $4.08, and its 52-week low was $1.56. It is currently -47.79% from its 52-week high and 36.54% from its 52-week low.

How much is Indaptus Therapeutics stock worth today?

(NASDAQ: INDP) Indaptus Therapeutics currently has 8,538,883 outstanding shares. With Indaptus Therapeutics stock trading at $2.13 per share, the total value of Indaptus Therapeutics stock (market capitalization) is $18.19M.

Indaptus Therapeutics stock was originally listed at a price of $480.00 in Aug 4, 2015. If you had invested in Indaptus Therapeutics stock at $480.00, your return over the last 8 years would have been -99.56%, for an annualized return of -49.2% (not including any dividends or dividend reinvestments).

How much is Indaptus Therapeutics's stock price per share?

(NASDAQ: INDP) Indaptus Therapeutics stock price per share is $2.13 today (as of Jul 19, 2024).

What is Indaptus Therapeutics's Market Cap?

(NASDAQ: INDP) Indaptus Therapeutics's market cap is $18.19M, as of Jul 21, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Indaptus Therapeutics's market cap is calculated by multiplying INDP's current stock price of $2.13 by INDP's total outstanding shares of 8,538,883.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.